Milestone Pharmaceuticals (MIST) Stock Forecast, Price Target & Predictions
MIST Stock Forecast
Milestone Pharmaceuticals stock forecast is as follows: an average price target of $10.00 (represents a 594.44% upside from MIST’s last price of $1.44) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
MIST Price Target
The average price target for Milestone Pharmaceuticals (MIST) is $10.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 594.44% upside from MIST's last price of $1.44.
MIST Analyst Ratings
According to 4 Wall Street analysts, Milestone Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for MIST stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Milestone Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 22, 2022 | - | Piper Sandler | $10.00 | $7.15 | 39.86% | 594.44% |
The latest Milestone Pharmaceuticals stock forecast, released on Apr 22, 2022 by Piper Sandler company, set a price target of $10.00, which represents a 39.86% increase from the stock price at the time of the forecast ($7.15), and a 594.44% increase from MIST last price ($1.44).
Milestone Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.44 | $1.44 | $1.44 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Milestone Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Milestone Pharmaceuticals's last price of $1.44. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 22, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Jul 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 27, 2023 | Cowen & Co. | Outperform | Outperform | Hold |
| Apr 26, 2022 | Piper Sandler | - | Overweight | Upgrade |
Milestone Pharmaceuticals's last stock rating was published by Cowen & Co. on Oct 21, 2024. The company gave MIST a "Buy" rating, the same as its previous rate.
Milestone Pharmaceuticals Financial Forecast
Milestone Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $3.50M | $15.00M |
| Avg Forecast | $4.23M | $2.07M | $433.33K | $433.33K | - | - | - | $1.17M | $5.00M |
| High Forecast | $4.23M | $2.07M | $433.33K | $433.33K | - | - | - | $1.17M | $5.00M |
| Low Forecast | $4.23M | $2.07M | $433.33K | $433.33K | - | - | - | $1.17M | $5.00M |
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | 3.00% | 3.00% |
Milestone Pharmaceuticals's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. MIST's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $3.50M (Dec 22).
Milestone Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-13.76M | $793.00K |
| Avg Forecast | $-845.70K | $-413.90K | $-86.67K | $-86.67K | - | - | - | $-233.33K | $-1000.00K |
| High Forecast | $-845.70K | $-413.90K | $-86.67K | $-86.67K | - | - | - | $-233.33K | $-1000.00K |
| Low Forecast | $-845.70K | $-413.90K | $-86.67K | $-86.67K | - | - | - | $-233.33K | $-1000.00K |
| Surprise % | - | - | - | - | - | - | - | 58.97% | -0.79% |
1 analysts predict MIST's average Quarter EBITDA for Dec 22 to be $-233.33K, with a high of $-233.33K and a low of $-233.33K. This is -129.42% lower than Milestone Pharmaceuticals's previous annual EBITDA (Jun 21) of $793.00K.
Milestone Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $18.26M | $770.00K |
| Avg Forecast | $-19.85M | $-18.86M | $-15.88M | $-13.23M | $-12.57M | $-10.75M | $-12.57M | $-22.17M | $-17.20M |
| High Forecast | $-19.85M | $-18.86M | $-15.88M | $-13.23M | $-12.57M | $-8.74M | $-12.57M | $-22.17M | $-17.20M |
| Low Forecast | $-19.85M | $-18.86M | $-15.88M | $-13.23M | $-12.57M | $-12.77M | $-12.57M | $-22.17M | $-17.20M |
| Surprise % | - | - | - | - | - | - | - | -0.82% | -0.04% |
Milestone Pharmaceuticals's average Quarter net income forecast for Jun 24 is $-12.57M, with a range of $-12.57M to $-12.57M. MIST's average Quarter net income forecast represents a -168.85% decrease compared to the company's last Quarter net income of $18.26M (Dec 22).
Milestone Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $6.68M | $4.86M |
| Avg Forecast | $32.81M | $16.06M | $3.36M | $3.36M | - | - | - | $9.05M | $38.80M |
| High Forecast | $32.81M | $16.06M | $3.36M | $3.36M | - | - | - | $9.05M | $38.80M |
| Low Forecast | $32.81M | $16.06M | $3.36M | $3.36M | - | - | - | $9.05M | $38.80M |
| Surprise % | - | - | - | - | - | - | - | 0.74% | 0.13% |
Milestone Pharmaceuticals's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to MIST last annual SG&A of $6.68M (Dec 22).
Milestone Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $0.43 | $0.02 |
| Avg Forecast | $-0.30 | $-0.28 | $-0.24 | $-0.20 | $-0.19 | $-0.16 | $-0.19 | $-0.34 | $-0.26 |
| High Forecast | $-0.30 | $-0.28 | $-0.24 | $-0.20 | $-0.19 | $-0.13 | $-0.19 | $-0.34 | $-0.26 |
| Low Forecast | $-0.30 | $-0.28 | $-0.24 | $-0.20 | $-0.19 | $-0.19 | $-0.19 | $-0.34 | $-0.26 |
| Surprise % | - | - | - | - | - | - | - | -1.28% | -0.08% |
According to 0 Wall Street analysts, Milestone Pharmaceuticals's projected average Quarter EPS for Jun 24 is $-0.19, with a low estimate of $-0.19 and a high estimate of $-0.19. This represents a -144.19% decrease compared to MIST previous annual EPS of $0.43 (Dec 22).
Milestone Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IVA | Inventiva | $2.75 | $36.00 | 1209.09% | Buy |
| CHRS | Coherus BioSciences | $0.72 | $9.00 | 1150.00% | Hold |
| SPRO | Spero Therapeutics | $1.18 | $10.00 | 747.46% | Buy |
| XFOR | X4 Pharmaceuticals | $0.52 | $3.67 | 605.77% | Buy |
| MIST | Milestone Pharmaceuticals | $1.44 | $10.00 | 594.44% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| CMPX | Compass Therapeutics | $1.70 | $5.00 | 194.12% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.65 | $38.80 | 164.85% | Buy |
| TERN | Terns Pharmaceuticals | $6.94 | $14.25 | 105.33% | Buy |
| NAMS | NewAmsterdam Pharma Company | $17.82 | $36.50 | 104.83% | Buy |
| CGEM | Cullinan Oncology | $15.78 | $31.50 | 99.62% | Buy |
| DMAC | DiaMedica Therapeutics | $4.25 | $8.33 | 96.00% | Buy |
| IKT | Inhibikase Therapeutics | $2.64 | $5.00 | 89.39% | Buy |
| MCRB | Seres Therapeutics | $0.82 | $1.25 | 52.44% | Buy |
| BOLT | Bolt Biotherapeutics | $0.66 | $1.00 | 51.52% | Hold |
| HOOK | HOOKIPA Pharma | $3.84 | $3.00 | -21.88% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
MIST Forecast FAQ
Is Milestone Pharmaceuticals a good buy?
Yes, according to 4 Wall Street analysts, Milestone Pharmaceuticals (MIST) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of MIST's total ratings.
What is MIST's price target?
Milestone Pharmaceuticals (MIST) average price target is $10 with a range of $10 to $10, implying a 594.44% from its last price of $1.44. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Milestone Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for MIST stock, the company can go up by 594.44% (from the last price of $1.44 to the average price target of $10), up by 594.44% based on the highest stock price target, and up by 594.44% based on the lowest stock price target.
Can Milestone Pharmaceuticals stock reach $2?
MIST's average twelve months analyst stock price target of $10 supports the claim that Milestone Pharmaceuticals can reach $2 in the near future.
What are Milestone Pharmaceuticals's analysts' financial forecasts?
Milestone Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-35.895M (high $-33.879M, low $-37.911M), average SG&A $0 (high $0, low $0), and average EPS is $-0.542 (high $-0.512, low $-0.573). MIST's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $7.16M (high $7.16M, low $7.16M), average EBITDA is $-1.433M (high $-1.433M, low $-1.433M), average net income is $-67.82M (high $-67.82M, low $-67.82M), average SG&A $55.59M (high $55.59M, low $55.59M), and average EPS is $-1.025 (high $-1.025, low $-1.025).
Did the MIST's actual financial results beat the analysts' financial forecasts?
Based on Milestone Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $5M, beating the average analysts forecast of $1.17M by 328.57%. Apple's EBITDA was $-59.642M, beating the average prediction of $-233K by 25460.89%. The company's net income was $-57.134M, beating the average estimation of $-22.165M by 157.76%. Apple's SG&A was $24.81M, beating the average forecast of $9.05M by 174.10%. Lastly, the company's EPS was $-1.35, beating the average prediction of $-0.335 by 302.99%. In terms of the last quarterly report (Dec 2022), Milestone Pharmaceuticals's revenue was $3.5M, beating the average analysts' forecast of $1.17M by 200.00%. The company's EBITDA was $-13.759M, beating the average prediction of $-233K by 5796.72%. Milestone Pharmaceuticals's net income was $18.26M, missing the average estimation of $-22.165M by -182.37%. The company's SG&A was $6.68M, missing the average forecast of $9.05M by -26.20%. Lastly, the company's EPS was $0.43, missing the average prediction of $-0.335 by -228.36%